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 Th e estimates of the prevalence of chronic 
kidney disease (CKD) in the developed 
world are staggering. In the United States, 
more than 13 % of adults are thought to 
have CKD, and more than 15 million peo-
ple are estimated to have stage 3 CKD. 1 It 
is also now well established that the risk of 
death primarily from cardiovascular causes 
for many people with CKD is much greater 
than that of progression of disease to end-
stage renal disease. 2 Th us, cardiovascular 
risk reduction is as central to the manage-
ment of CKD as is slowing the progression 
of disease. Advances that have been made 
in the care of these patients include better 
defi nitions for staging of CKD, improved 
guidelines for referral to a specialist, and a 
better understanding of risk factors associ-
ated with higher cardiovascular risk. How-
ever, there are two enormous challenges 
that limit our ability to provide eff ective 
care for CKD. First, the size of the CKD 
population is too large for eff ective mitiga-
tion of cardiovascular risk and slowing of 
progression of disease to be achieved by 
nephrologists alone. Second, targets for 
cardiovascular risk factor modifi cation for 
people with CKD are largely based on 
observational data, as there is a paucity of 
high-level clinical trial evidence. Thus, 
there is a compelling need not only to 
develop cost-eff ective care models that 
incorporate other health-care providers in 
the delivery of care to this high-risk popu-
lation but also to develop high-level evi-
dence to better defi ne therapeutic targets. 
 Van Zuilen  et al. 3 (this issue) address 
this important topic in the presentation 
of the results of the MASTERPLAN 
(Multifactorial Approach and Superior 
Treatment Effi  cacy in Renal Patients with 
the Aid of Nurse practitioners) study. Th e 
investigators randomized 788 subjects 
with CKD (estimated creatinine clearance 
20 – 70  ml / min), including 110 people with 
a functioning renal transplant, to standard 
care by a nephrologist or intensive sup-
port by a nurse practitioner. Both groups 
were educated on care guidelines, which 
consisted of four areas of lifestyle modifi -
cation (physical activity, nutrition coun-
seling, weight reduction, and smoking 
cessation), achievement of therapeutic 
targets for 11 putative risk factors ( Table 1 ), 
and maximization of the use of four groups 
of medications (statins, inhibitors of the 
renin – angiotensin system, active vitamin 
D, and aspirin). 3 During the mean follow-
up of 4.62 years, intensive nurse practi-
tioner support was associated with small 
but signifi cant improvements in blood 
pressure control, low-density lipoprotein 
cholesterol levels, and urine protein excre-
tion, hemoglobin levels were higher, and 
there was a greater use of antihypertensive 
medications, statins, active vitamin D, and 
aspirin. Th ere was, however, no diff erence 
in the ability of two treatment approaches 
to achieve lifestyle modifi cation. More 
importantly, the small improvements 
in risk factor control did not translate 
into a reduction in risk in the composite 
outcome of myocardial infarction, 
ischemic stroke, or cardiovascular death. 3 
Furthermore, there was no diff erence in 
the rate of progression to end-stage renal 
disease. 3 
 Th is study is very important for under-
standing how best to develop novel care 
models for management of people with 
CKD. Th ere are two potential reasons for 
the investigators to have been unable to 
reject the null hypothesis. As the results of 
the study suggest, intensive support by 
nurse practitioners may be no better than 
good care by nephrologists alone. Alterna-
tively, the investigators may have selected 
risk factors and / or therapeutic targets that 
were inappropriate, or the magnitude 
of change achieved may not have been 
suffi  cient to aff ect the outcomes. 
 Care models that incorporate nurse 
practitioners are increasingly being used 
in many parts of the world for the man-
agement of chronic diseases such as con-
gestive heart failure and diabetes mellitus. 4 
Given the demonstrable success in other 
fi elds, the large size of the at-risk popula-
tion, and the limited availability of trained 
nephrologists for the number of patients, 
it is prudent to test care models for CKD 
in which physicians partner with nurse 
practitioners to deliver care. In testing 
such care models, success could be defi ned 
in more than one way. Unquestionably, if 
the intensive care with the support of 
nurse practitioners results in tangible 
improvement in  ‘ hard ’ outcomes such as 
major adverse cardiovascular events, or 
all-cause mortality, or progression to end-
stage renal disease, the model would be 
deemed successful. However, to date there 
is no evidence to support such a claim. 
While the MASTERPLAN study showed 
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small improvements in risk factor control, 
there was no tangible eff ect on  ‘ hard ’ med-
ical outcomes. 3 In another randomized 
controlled clinical trial ( n  =  474), there 
was no diff erence in risk factor manage-
ment for CKD patients with intensive 
care coordinated by a nurse; however, the 
follow-up was too short to ascertain the 
eff ect on  ‘ hard ’ outcomes. 5 Conversely, in 
a single-center retrospective study, inci-
dent dialysis patients followed in a clinic 
including a nurse practitioner had higher 
hemoglobin and serum albumin levels, a 
greater likelihood of having a functioning 
permanent access, and, in the fi rst year of 
renal replacement therapy, fewer hospi-
talizations. 6 Given the mixed bag of evi-
dence, the case that incorporating nurse 
practitioners improves clinical outcomes 
in kidney disease has not been convinc-
ingly made thus far. 
 One of the premises for the use of physi-
cian extenders in the delivery of care for 
chronic diseases is that they are amenable 
to treatment with a limited number of 
standardized protocols. Th is necessitates a 
common disease pathway and common 
areas of risk factor management in an 
easily identifi able group. CKD does meet 
some of these characteristics. Despite the 
heterogeneous etiology of kidney disease, 
there are common pathways of hyper-
fi ltration, tubulointerstitial injury, and sys-
temic abnormalities (namely anemia, 
mineral metabolism, metabolic acidosis) 
that ensue. 7 However, important diff er-
ences also exist. Th ose with overt protein-
uria may have greater benefi ts with the use 
of inhibitors of the renin – angiotensin – aldo-
sterone system. Despite these advantages, 
our ability to ameliorate cardiovascular 
risk depends on targeting the appropriate 
risk factors. Unfortunately, there is a 
paucity of high-level evidence regarding 
cardiovascular risk in CKD populations. 
In the MASTERPLAN study, the investiga-
tors selected four targets for lifestyle modi-
fi cation and 11 putative risk factors and 
chose to maximize use of four therapeutic 
agents. 3 It is biologically plausible that the 
risk factors selected in the study increase 
cardiovascular risk, and virtually all of 
them are potentially modifi able ( Table 1 ). 
However, the epidemiologic evidence link-
ing many of these risk factors with cardio-
vascular outcomes is either inconsistent or 
converse of what is seen in the general 
population ( Table 1 ). More over, except for 
lipid lowering with statins, there is no 
clinical trial evidence that favorably mod-
ifying risk factors mitigates cardiovascular 
risk ( Table 1 ). 8 To the contrary, there is 
evidence that attempts to modify one of 
the risk factors selected in this study — to 
normalize hemoglobin levels — may 
increase cardiovascular risk in people with 
CKD. 9 It is, thus, impor tant to consider 
that the inability of the MASTERPLAN 
study to demonstrate benefi t with intensive 
care may conceivably be more a refl ection 
of the risk factors that they selected and 
the therapeutic targets they set than of 
the effi  cacy of the care model with nurse 
practitioners. Furthermore, patients with 
a functioning transplant have unique needs 
arising from acute and chronic rejection, 
and use of immunosuppressive medi-
cations, including glucocorticoids. It is 
possible that the study of a heterogeneous 
CKD population that included transplant 
recipients may have further limited 
the ability of the study to reject the null 
hypothesis. 
 Another threat to the external validity 
of the study is the occurrence of  ‘ contami-
nation bias ’ introduced by the education 
of both groups of health providers to the 
therapeutic targets. Consequently, though 
intensive care resulted in statistically 
signifi cant improvement in the control 
of some risk factors and increased the use 
of some selected drugs, the diff erences 
from the control group were small and of 
questionable clinical signifi cance. Juxta-
posing this small difference with the 
very large benefi t (50 % risk reduction) 
considered in the power calculations, 
the study was clearly underpowered to 
demonstrate lower risk for reaching the 
primary outcome. 
 Despite the lack of eff ect on  ‘ hard ’ out-
comes, nurse practitioner care would be 
equally valuable if similar care could be 
delivered but at a lower cost. It would 
appear at fi rst glance that an increasing 
use of nurse practitioners would be 
 Table 1  |  Evidence for the importance of risk factors targeted in the MASTERPLAN 
study to reduce cardiovascular risk in CKD patients 
 Therapeutic 
target 
 Association 
plausible with 
CVD in CKD 
 Epidemiologic 
evidence linking 
risk factor to 
CVD in CKD  Modifi able 
 RCT evidence that 
modifi cation 
reduces CVD risk 
 Blood pressure  Yes  J-shaped  Yes  No 
 Urinary protein 
excretion 
 Yes  Yes  Yes  No 
 LDL cholesterol  Yes  No; lower death 
risk with higher 
cholesterol or no 
association 
 Yes  Yes 
 Hemoglobin  Yes  Yes  Yes  Increased risk with 
higher targets 
 Glycemic 
control 
 Yes  Inconsistent  Yes  No 
 Serum 
phosphorus 
 Yes  Yes  Yes  No 
 Serum parathy-
roid hormone 
 Yes  Inconsistent  Yes  No 
 Urinary sodium 
excretion 
 Yes  No  Yes  No 
 Obesity  Yes  Lower death risk 
with larger body 
size 
 Yes  No 
 Physical exercise  Yes  Yes  Yes  No 
 Smoking  Yes  Yes  Yes  No 
 Abbreviations: CKD, chronic kidney disease; CVD, cardiovascular disease; LDL, low-density lipoprotein; 
RCT, randomized controlled clinical trial. 
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cost-eff ective. At least one previous study 
has suggested such an economic benefi t 
with the use of nurse practitioners. 5 
Whether it indeed was the case in the 
MASTERPLAN study, however, is unclear. 
Patients randomized to intensive care had 
signifi cantly more visits to the health-care 
facility (7.2 vs. 4.7); however, there were 
signifi cantly fewer visits to a nephrologist 
(2.8 vs. 3.7). 3 It is imperative that future 
studies incorporate cost-effectiveness 
analyses to evaluate care models using 
nurse practitioners more comprehensively. 
Alternatively, nurse practitioner care could 
be valuable if they focused on aspects of 
care different from those dealt with by 
nephrologists and / or if their mandate were 
more limited than what was attempted in 
the MASTERPLAN study. Physician visits 
are oft en rushed without insuffi  cient time 
to fully address each aspect of care, and 
nurse practitioners could supplement areas 
where care is beleaguered. 
 In conclusion, the MASTERPLAN 
trial is a very important study, and both its 
successes and its failures will inform deci-
sion making for the inevitable development 
of care models that incorporate physician 
extenders in the care of the high-risk CKD 
population. Th e future success of these care 
models depends on our ability to develop 
high-level evidence to correctly identify 
risk factors to be targeted to mitigate car-
diovascular risk and disease progression, 
determine the correct division of labor, and 
ensure that such care is cost-eff ective. 
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 The risks of vascular access 
 Peter G.  Blake 1 ,  Robert R.  Quinn 2 and  Matthew J.  Oliver 3 
 Fatal vascular access hemorrhage is considered a rare complication of 
hemodialysis (HD). Ellingson  et al. indicate otherwise, and their data 
suggest that it causes 0.4 – 1.6 % of deaths in US HD patients. It is more 
common with grafts than fistulas, and many victims have had previous 
access hemorrhages. The widespread presumption that a fistula is the 
best, and a cuffed catheter the worst, access for HD patients needs 
reassessment, particularly in older, sicker patients. 
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 Most nephrologists with any experience 
of hemodialysis (HD) will have seen cases 
of severe vascular access hemorrhage 
requiring urgent surgical inter vention, 
and some will recall fatalities. However, 
it is likely that most would consider 
this complication a rare cause of death, 
and, until now, there has been little in 
the literature to suggest otherwise. For 
this reason, the paper by Ellingson  et al. 1 
(this issue) is both surprising and impor-
tant. Th e investigators from the Centers 
for Disease Control and Prevention 
became involved when a cluster of such 
deaths was noticed in Maryland, Virginia, 
and the District of Columbia. A regional 
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investigation identifi ed 88 fatal vascular 
access hemorrhage (FVAH) deaths over 
a 6 – year period and noted that only a 
quarter of these cases had been identifi ed 
on Centers for Medicare and Medicaid 
Services (CMS) death reports. Across 
the United States, a startling 1654 deaths 
were identified from CMS data in the 
same period, accounting for 0.4 % of 
all HD deaths. However, if the same 
underestimation had occurred nation-
wide, the true number of HD deaths 
due to FVAH might be more than 6000, 
corresponding to at least 1000 annually 
or 1.6 % of all HD deaths. 
 Th e authors then investigated 88 cases 
in detail and made important observa-
tions. A large majority of the bleeds began 
in the patient ’ s residence and not in the 
dialysis unit. More than half involved 
an arteriovenous graft . Th e mean age of 
the patients was only 64 years, and only 
a very small number of cases appear 
to have been episodes of  ‘ self-harm ’ . 
Compared with case controls, the victims 
were more likely to have had graft s and to 
be long-term HD patients, and, most 
